Haemonetics Corporation $HAE Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its stake in shares of Haemonetics Corporation (NYSE:HAE) by 131.9% during the first quarter, Holdings Channel.com reports. The firm owned 177,401 shares of the medical instruments supplier’s stock after acquiring an additional 100,910 shares during the period. Assenagon Asset Management S.A.’s holdings in Haemonetics were worth $9,998,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of HAE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after buying an additional 971 shares in the last quarter. Caxton Associates LLP bought a new stake in shares of Haemonetics during the 1st quarter worth about $216,000. United Services Automobile Association bought a new stake in shares of Haemonetics during the 1st quarter worth about $212,000. Empowered Funds LLC lifted its stake in shares of Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Haemonetics by 6.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on HAE. JPMorgan Chase & Co. lowered their price objective on shares of Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. BTIG Research restated a “buy” rating and issued a $84.00 price objective on shares of Haemonetics in a report on Friday. Barrington Research decreased their target price on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday. Finally, Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $78.33.

Haemonetics Trading Up 0.1%

NYSE:HAE opened at $77.34 on Monday. The stock has a fifty day simple moving average of $65.41 and a 200 day simple moving average of $66.76. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of 38.29, a price-to-earnings-growth ratio of 1.56 and a beta of 0.55. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The business had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same quarter in the previous year, the business earned $1.24 earnings per share. The firm’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts forecast that Haemonetics Corporation will post 5.22 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.